MDMs depletion effectively inhibits liver fibrosis progression in Tet2 ^ΔMye mice. (A and B) IF assay (A) (scale bar, 400 μm) and statistical analysis (B) of MDMs infiltration in livers of oil- or CCl₄-treated Tet2^WT and Tet2^ΔMye mice. Blue: DAPI, red: anti-F4/80, and green: anti-Ly6c (n = 4 for each group). (C and D) Frequency of CD86⁺ MDMs (M1) (C) and CD206⁺ MDMs (M2) (D) evaluated by flow cytometry in livers of oil- or CCl₄-treated Tet2^WT and Tet2^ΔMye mice (n = 4 for each group). (E and F) Representative flow cytometry graphs (E) and statistical analysis (F) the of MDMs frequency in Tet2^WT and Tet2^ΔMye mice after treatment with PBS-Lip or Clod-Lip (n = 3 for each group). (G–I) Picrosirius red staining (G and H) (scale bar, 125 μm) and Ishak score (I) in livers of PBS-Lip– and Clod-Lip–treated Tet2^WT and Tet2^ΔMye mice with liver fibrosis. (J–L) IHC staining (J) and statistical analysis of α-SMA (K) and collagen I (L) expression in livers (scale bar, 100 μm) of PBS-Lip– and Clod-Lip–treated Tet2^WT and Tet2^ΔMye mice (n = 3 for each group). (M and N) Changes in serum Col IV (M) and HA (N) in CCl₄-treated Tet2^WT and Tet2^ΔMye mice after PBS-Lip or Clod-Lip treatment (n = 4 for each group). Data are representative of at least two independent experiments with similar results (A–N). All data are shown as mean ± SD and were analyzed by two-way ANOVA with Sidak’s multiple comparison test (B–D, F, H, I, and K–N). ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns).